Telomere dysfunction in ageing and age-related diseases
Most protocols recommend 4-8 weeks on, followed by 2-4 weeks off
adultsup from roughly 30% in 2000access to GLP-1 therapies is inconsistent across demographic and socioeconomic groups
Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications: Pickart et al
We still need to identify which patient populations will benefit the most for long-term health outcomes, especially if costs remain so high
At the time of this writing, liraglutide is the only GLP-1 RA with a labeled indication to reduce the risk of major adverse cardiovascular events (MACE), yet several other GLP-1 RAs have shown significant reduction in MACE, as summarized in Table 2